Exhibit 99.1 Ascent Industries Co. Delivers Strongest Earnings Since 2022; Gross Profit Nearly Doubles Year-Over-Year Schaumburg, Illinois, November 4, 2025 – Ascent Industries Co. (Nasdaq: ACNT) ("Ascent" or the "Company"), a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions, is reporting its results for the third quarter ended September 30, 2025. Third Quarter 2025 Summary 1 Net sales from continuing operations were $19 ...

Financial Performance - Net product revenue for the three and nine months ended September 30, 2025, was $77,467 and $198,107, respectively, compared to $50,025 and $118,707 for the same periods in 2024, indicating a significant increase driven by the early phases of LUMRYZ launch [187]. - Gross profit for the three and nine months ended September 30, 2025, was $81,583 and $190,280, respectively, compared to $43,870 and $108,242 for the same periods in 2024, reflecting a decrease in the cost of products sold [187]. - Operating income for the nine months ended September 30, 2025, was $7,820, a significant improvement from an operating loss of $39,102 in the same period of 2024 [191]. - Diluted net income per share for the nine months ended September 30, 2025, was $0.05, compared to a diluted net loss per share of $0.46 in the same period of 2024 [191]. - The net income for the nine months ended September 30, 2025, was $4,765, contributing to the positive cash flow from operating activities [203]. - Cash, cash equivalents, and marketable securities increased by $17,800 to $91,577 as of September 30, 2025, primarily due to net cash provided by operating activities of $26,670 [190]. - Net cash provided by operating activities for the nine months ended September 30, 2025, was $26,670, a significant increase of $81,450 or 148.7% compared to a net cash used of $54,780 in the same period of 2024 [202][203]. - Investment and other income, net decreased by $2,219 or 71.3% during the nine months ended September 30, 2025, primarily due to lower interest income and higher foreign exchange losses [198]. - Income tax benefit increased by $2,731 or 835.2% during the nine months ended September 30, 2025, driven by the release of uncertain tax positions [200]. Product Development and Regulatory Approvals - LUMRYZ received FDA approval on May 1, 2023, for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy, with seven years of Orphan Drug Exclusivity granted until May 1, 2030 [175]. - A pivotal trial named REVITALYZ has been initiated to evaluate the efficacy and safety of LUMRYZ in treating idiopathic hypersomnia, with an expected enrollment of approximately 150 adults and completion anticipated by the end of 2025 [179]. - LUMRYZ has been granted Orphan Drug Designation for the treatment of idiopathic hypersomnia, based on its potential clinical superiority due to its once-nightly dosing regimen [181]. Expenses and Financial Management - Research and development expenses increased by $24,697 or 226.1% during the nine months ended September 30, 2025, primarily due to $20,000 upfront license fees to XWPharma and costs associated with clinical trials [195]. - Selling, general and administrative expenses rose by $10,419 or 7.6% during the nine months ended September 30, 2025, driven by higher employee-related costs and commercial expenses for LUMRYZ [197]. - The company has a history of net losses from operations, although it was profitable in the quarters ended June 30, 2025, and September 30, 2025 [187]. Strategic Agreements and Transactions - A Settlement and License Agreement was entered into with Jazz Pharmaceuticals on October 21, 2025, resolving multiple lawsuits related to LUMRYZ [182]. - A Transaction Agreement was announced with Alkermes on October 22, 2025, under which Alkermes will acquire Avadel for $18.50 in cash per share, plus a potential additional cash payment of $1.50 per share contingent on specified milestones [183][184]. - The transaction with Alkermes is expected to close in the first quarter of 2026, subject to customary closing conditions including shareholder approval and antitrust clearances [185]. - The company has entered into a Transaction Agreement with Alkermes, which imposes certain operational restrictions but does not hinder funding for operations and capital expenditures [201]. Market and Competitive Landscape - The competitive landscape includes the launch of authorized generic versions of sodium oxybate, which may impact LUMRYZ's market position [187]. - The number of patients treated with LUMRYZ increased to approximately 3,400 as of September 30, 2025, compared to approximately 2,300 patients a year earlier [192]. Cash Flow and Capital Management - Net cash used in investing activities was $4,370 for the nine months ended September 30, 2025, compared to net cash provided of $36,867 in the same period of 2024, reflecting a change of $41,237 or (111.9)% [202][204]. - Net cash provided by financing activities was $4,179 for the nine months ended September 30, 2025, a decrease of $10,911 or (72.3)% from $15,090 in the same period of 2024 [202][205]. - The company anticipates sufficient capital from existing cash, cash equivalents, and marketable securities, along with expected sales from LUMRYZ, to meet operating and capital requirements for the next twelve months [207]. Legal and Regulatory Considerations - The company is subject to potential liabilities from lawsuits and claims, but there were no contingent liabilities as of September 30, 2025, that could materially affect financial position [208]. - The company does not believe inflation had a material effect on its financial condition or results of operations during the nine months ended September 30, 2025, but acknowledges potential future impacts [212]. - A 10% change in foreign currency exchange rates related to euro-denominated assets would have had an immaterial impact on net income for the nine months ended September 30, 2025 [210].

Revenue Performance - Total Annual Recurring Revenue (ARR) for Q3 2025 was $1.490 billion, a 1% increase year-over-year, remaining flat in constant currency[3] - Total revenue for Q3 2025 was $416 million, a decrease of 5% as reported and 6% in constant currency compared to Q3 2024[4] - Recurring revenue was $366 million, down 2% as reported and 3% in constant currency from the previous year[4] - Recurring revenue for the nine months ended September 30, 2025, was $1,078 million, down 4% from $1,128 million in the same period of 2024[18] - Total segment revenue decreased by 5% to $416 million for the three months ended September 30, 2025, down from $440 million in 2024[24] - Product sales revenue declined by 3% to $369 million in Q3 2025, compared to $379 million in Q3 2024[24] - Consulting services revenue saw a significant drop of 23%, falling to $47 million from $61 million year-over-year[24] Earnings and Margins - GAAP diluted EPS for Q3 2025 was $0.42, compared to $0.33 per share in Q3 2024, marking a 27% increase[7] - Non-GAAP diluted EPS for Q3 2025 was $0.72, up from $0.69 per share in the same quarter last year[7] - GAAP Earnings Per Share for Q3 2025 was $0.42, up from $0.33 in Q3 2024, representing a 27.3% increase[13] - Non-GAAP Diluted Earnings Per Share for Q3 2025 was $0.72, compared to $0.69 in Q3 2024, indicating a 4.3% increase[13] - GAAP gross margin improved to 60.8% from 60.5% year-over-year[4] - Non-GAAP operating margin increased to 23.6% from 22.5% in the prior year[7] Cash Flow and Capital Expenditures - Free cash flow for Q3 2025 was $88 million, compared to $69 million in Q3 2024, reflecting a 28% increase[7] - Free Cash Flow for Q3 2025 was $88 million, compared to $69 million in Q3 2024, reflecting a 27.5% increase[14] - The company anticipates free cash flow for 2025 to be between $260 million and $280 million[14] - Total capital expenditures for the nine months ended September 30, 2025, were $20 million, compared to $18 million in the same period of 2024[14] Net Income and Assets - The company reported a net income of $40 million for Q3 2025, an increase from $32 million in Q3 2024, representing a 25% increase[18] - Net income for the three months ended September 30, 2025, was $40 million, compared to $32 million for the same period in 2024, reflecting a year-over-year increase of 25%[22] - Total assets increased to $1,761 million as of September 30, 2025, up from $1,704 million at December 31, 2024, representing a growth of 3.35%[20] - Total current liabilities decreased slightly to $906 million as of September 30, 2025, from $930 million at December 31, 2024[20] - Total stockholders' equity rose to $219 million as of September 30, 2025, compared to $133 million at December 31, 2024[20] Guidance and Outlook - The company reaffirms its full-year 2025 outlook for Total ARR, Cloud ARR, and Free Cash Flow[5] - The company expects 2025 full-year GAAP EPS guidance to be between $1.22 and $1.26[13] - The non-GAAP effective tax rate for Q3 2025 was 23.3%, down from 25.6% in Q3 2024[13] Stock Repurchase - The company repurchased $30 million of common stock during the three months ended September 30, 2025, compared to $15 million in the same period of 2024[22]

Financial Performance - Q3 2025 revenue was $170.4 million, up 2% compared to Q3 2024[5] - Net income for Q3 2025 was $20.5 million, representing a 79% increase year-over-year[5] - Operating income grew 114% year-over-year to $22.7 million, or 13.3% of revenue[5] - Gross margin improved to 55.2%, up from 46.1% in Q3 2024[5] - Platform revenue reached $82.8 million, up 7% over Q3 2024[5] - Total revenue for Q3 2025 was $170,437,000, a 1% increase from $167,890,000 in Q3 2024[21] - Gross profit for Q3 2025 reached $94,096,000, compared to $77,363,000 in Q3 2024, marking a 21.5% increase[21] - Net income for the nine months ended September 30, 2025, was $68,914,000, up 35.4% from $50,904,000 in the same period of 2024[21] - Earnings per share (diluted) for Q3 2025 was $0.10, compared to $0.05 in Q3 2024[21] - Diluted earnings per share rose to $0.10, up from $0.05 in Q3 2024[5] Subscriber Growth - Over 3 million paid subscribers, an increase of 6% from Q3 2024[10] Revenue Sources - International revenue increased by 5% year-over-year, accounting for 24% of total revenue[5] Cash Flow and Dividends - Generated $20 million in cash from operations during Q3 2025[4] - The company plans to pay a recurring semi-annual dividend of $0.10 per share in January 2026[4] - The company reported a net cash provided by operating activities of $117,798,000 for the nine months ended September 30, 2025[25] Expenses and Liabilities - Operating expenses for Q3 2025 totaled $71,445,000, an increase of 7.5% from $66,767,000 in Q3 2024[21] - Cash and cash equivalents decreased to $187,873,000 as of September 30, 2025, down from $232,140,000 at the end of 2024[23] - Total current assets decreased to $441,098,000 as of September 30, 2025, compared to $580,214,000 as of December 31, 2024[23] - Total liabilities decreased to $205,862,000 as of September 30, 2025, from $226,274,000 as of December 31, 2024[23] Stock Repurchase - The company repurchased common stock amounting to $19,094,000 during the nine months ended September 30, 2025[25]

Financial Performance - In Q3 2025, BlueLinx reported net sales of $749 million, a slight increase of $2 million or 0.2% compared to Q3 2024[5] - Gross profit for the quarter was $108 million, down $17 million or 14% year-over-year, with a gross margin percentage of 14.4%, a decrease of 240 basis points from the previous year[5] - Net income for the quarter was $1.7 million, or $0.20 per diluted share, compared to $16.0 million, or $1.87 per diluted share in the prior year[11] - Adjusted EBITDA was $22.4 million, or 3.0% of net sales, down from $36.6 million, or 4.9% of net sales in Q3 2024[12] - Adjusted EBITDA for the three fiscal months ended September 27, 2025, was $9,966,000, compared to $24,025,000 for the same period in 2024, indicating a decline in operating performance[38] - Operating income for the three months ended September 27, 2025, was $9,966,000, a significant decrease from $24,025,000 in the same period of 2024[38] - Net income for the three months ended September 27, 2025, was $1,655,000, down from $16,016,000 in the same period last year, representing a decline of approximately 89.7%[38] - Basic earnings per share for the three months ended September 27, 2025, were $0.20, compared to $1.88 for the same period in 2024, indicating a substantial decrease[38] Sales Performance - Specialty product net sales reached $525 million, an increase of $6 million or 1.2% year-over-year, driven by higher volumes in engineered wood products and outdoor living[6] - Structural product net sales decreased by $4.9 million or 2.1% year-over-year to $223 million, primarily due to volume and price declines in lumber and panels[7] - Net sales for the three fiscal months ended September 27, 2025, were $748,870,000, slightly up from $747,288,000 in the same period last year, reflecting a marginal growth of 0.2%[38] - Total net sales for the three fiscal months ended September 27, 2025, were $748,870,000, slightly up from $747,288,000 in the prior year[44] - Specialty products net sales for the three fiscal months ended September 27, 2025, were $525,455,000, compared to $519,000,000 in the same period last year[44] Cash Flow and Liquidity - The company generated free cash flow of $53 million during the quarter, with net cash provided by operating activities at $59 million[13] - Free cash flow is defined as net cash provided by operating activities less total capital expenditures, which is a key measure for assessing financial performance[35] - Cash flows from operating activities for the three fiscal months ended September 27, 2025, were $58,616,000, compared to $61,766,000 for the same period in 2024[42] - The company reported a net cash used in investing activities of $5,927,000 for the three fiscal months ended September 27, 2025[42] - The company’s cash and cash equivalents at the end of the period were $429,360,000, down from $526,281,000 at the end of the previous year[42] - The company has available cash and cash equivalents of $429.4 million as of September 27, 2025, down from $505.6 million as of December 28, 2024[51] Debt and Liabilities - As of September 27, 2025, total debt was $380 million, with available liquidity of $777 million, including $429 million in cash[15] - As of September 27, 2025, total debt and finance leases amount to $621.8 million, an increase from $592.5 million as of December 28, 2024[51] - Net debt (non-GAAP) stands at $192.4 million as of September 27, 2025, compared to $86.9 million as of September 28, 2024[51] - The net leverage ratio is 2.1x as of September 27, 2025, compared to 0.7x as of September 28, 2024[51] - Total liabilities as of September 27, 2025, were $958,946,000, compared to $931,276,000 as of December 28, 2024, indicating an increase in financial obligations[40] Equity and Assets - Total current assets as of September 27, 2025, were $1,098,924,000, a decrease from $1,133,988,000 as of December 28, 2024[40] - Total stockholders' equity decreased to $623,018,000 as of September 27, 2025, down from $646,441,000 as of December 28, 2024, reflecting a decline in shareholder value[40] Acquisition - BlueLinx announced the acquisition of Disdero Lumber Company for approximately $96 million, expected to be immediately accretive to earnings[16] Future Outlook - The outlook for Q4 2025 indicates specialty product gross margin in the range of 17% to 18% and structural product gross margin in the range of 8% to 9%[17]

Financial Performance - Total revenue for Q3 2025 was approximately $69.5 million, including record net product sales of $64.1 million, a 65% increase from $38.9 million in Q3 2024[5][8] - Net product sales of TAVALISSE reached $44.7 million, a growth of 70% compared to $26.3 million in the same period of 2024[8][6] - GAVRETO net product sales were $11.1 million, reflecting a 56% increase from $7.1 million in Q3 2024[8][6] - REZLIDHIA net product sales amounted to $8.3 million, a 50% increase from $5.5 million in Q3 2024[8][6] - The company generated a net income of $27.9 million, or $1.55 basic and $1.46 diluted per share, compared to $12.4 million, or $0.71 basic and diluted per share, for the same period of 2024[10] - For the nine months ended September 30, 2025, total revenues were $224.5 million, with net product sales growing 69% compared to $98.4 million in the same period of 2024[12] - Total revenues for Q3 2025 reached $69,462,000, a 25.5% increase from $55,307,000 in Q3 2024[32] - Product sales for Q3 2025 were $64,067,000, up 64.5% compared to $38,927,000 in Q3 2024[32] - Net income for the nine months ended September 30, 2025, was $98,959,000, significantly higher than $3,144,000 for the same period in 2024[32] Guidance and Expectations - Rigel updated its 2025 revenue guidance to approximately $285 to $290 million, up from the previous range of $270 to $280 million[15] - The company anticipates continued growth in its commercial business and ongoing enrollment in the R289 study[29] - Rigel expects to develop and commercialize TAVALISSE, GAVRETO, and REZLIDHIA in domestic and international markets[29] Costs and Expenses - Total costs and expenses for Q3 2025 were $41.0 million, slightly down from $41.3 million in Q3 2024[9] - Research and development expenses for Q3 2025 were $7,353,000, compared to $6,182,000 in Q3 2024, reflecting a 19% increase[32] - Selling, general and administrative expenses for the nine months ended September 30, 2025, totaled $85,908,000, slightly up from $83,539,000 in the same period of 2024[32] Cash and Equity - Cash, cash equivalents, and short-term investments as of September 30, 2025, were $137.1 million, compared to $77.3 million as of December 31, 2024[14] - Cash, cash equivalents, and short-term investments increased to $137,143,000 as of September 30, 2025, compared to $77,321,000 as of December 31, 2024[34] - Stockholders' equity rose to $117,609,000 as of September 30, 2025, a substantial increase from $3,288,000 as of December 31, 2024[34] Research and Development - The ongoing Phase 1b study evaluating R289 for lower-risk MDS has completed enrollment in the dose escalation phase and initiated the dose expansion phase[5][6] Risks and Challenges - Forward-looking statements indicate potential risks related to regulatory approvals and market competition affecting future performance[29]

Financial Performance - Total revenue for Q2 FY 2026 was $184.1 million, a year-over-year increase from $181.0 million in Q2 FY 2025[5] - Service revenue for Q2 FY 2026 reached $179.1 million, compared to $175.1 million in the same quarter last year[5] - GAAP net income for Q2 FY 2026 was $0.8 million, a significant improvement from a net loss of $14.5 million in Q2 FY 2025[5] - Non-GAAP net income for Q2 FY 2026 was $13.1 million, up from $12.1 million in Q2 FY 2025[5] - Total revenue for Q2 2025 was $184.1 million, a 1.2% increase from $181.0 million in Q2 2024[36] - Service revenue reached $179.1 million, up from $175.1 million year-over-year, indicating a growth of 1.2%[36] - Net income for Q2 2025 was $767,000, a significant improvement from a net loss of $14.5 million in Q2 2024[36] - Basic and diluted net income per share for Q2 2025 was $0.01, compared to a loss of $0.11 per share in Q2 2024[36] - GAAP net income for Q3 2025 was $767, representing 0.4% of total revenue, a significant improvement from a loss of $14,543 in Q3 2024, which was -8.0% of total revenue[43] - Non-GAAP net income for Q3 2025 reached $13,113, or 7.1% of total revenue, compared to $12,099, or 6.7% in Q3 2024[43] Cash Flow and Expenses - Cash flow from operations for Q2 FY 2026 was $8.8 million, down from $12.3 million in Q2 FY 2025[5] - Total operating expenses decreased slightly to $114.0 million from $116.0 million year-over-year[36] - Cash and cash equivalents as of September 30, 2025, were $75.9 million, down from $88.1 million at the end of March 2025[38] - Total assets decreased to $670.8 million from $683.2 million since March 31, 2025[38] - Stockholders' equity increased to $133.2 million from $122.2 million since March 31, 2025[38] - Net cash provided by operating activities for the six months ended September 30, 2025, was $20,708, compared to $30,465 for the same period in 2024, representing a decrease of 32.2%[40] - Cash, cash equivalents, and restricted cash at the end of the period were $76,684, down from $117,867 at the end of the previous year[40] Profitability Metrics - Non-GAAP operating margin for FY 2026 is projected to be between 8.5% and 9.5%[19] - GAAP service revenue margin for the six months ended September 30, 2025, was 68.6%, down from 71.3% in 2024[42] - Non-GAAP gross margin as a percentage of total revenue for the six months ended September 30, 2025, was 66.7%, compared to 70.4% in 2024[42] - Non-GAAP operating profit for the six months ended September 30, 2025, was $33,657, down from $41,648 in 2024, reflecting a decrease of 19.2%[42] - Adjusted EBITDA for Q3 2025 was $22,037, accounting for 12.0% of total revenue, down from $26,650, or 14.7% in Q3 2024[43] Debt and Capital Management - The company has reduced total debt by $224 million, or 41%, since August 2022, reflecting a commitment to disciplined capital management[12] - The company incurred $25,000 in principal repayment on term loans during the six months ended September 30, 2025[40] - The company reported a loss on debt extinguishment of $46 in Q3 2025, compared to a significant loss of $11,996 in Q3 2024[43] Recognition and Innovation - 8x8 was recognized as a leader in the IDC MarketScape for European Contact Center-as-a-Service Applications Software 2025[12] - The company introduced AI-powered features to enhance agent productivity and improve service quality in the contact center[12] Stock-Based Compensation - Stock-based compensation expense for the six months ended September 30, 2025, was $12,671, compared to $23,438 in 2024, indicating a reduction of 46%[42] - Stock-based compensation expense for Q3 2025 was $5,762, down from $9,845 in Q3 2024[43]

Revenue and Income - Total revenues for the three months ended September 30, 2025, increased to $379.745 million, up from $253.912 million in the same period of 2024, representing a 49.5% increase[10] - For the nine months ended September 30, 2025, total revenues reached $968.038 million, compared to $643.771 million in the same period of 2024, marking a 50.4% increase[11] - Total revenues for the nine months ended September 30, 2025, increased to $1,024,395 thousand, up 42.5% from $718,258 thousand in the same period of 2024[12] - Net income attributable to common stockholders for the three months ended September 30, 2025, was $81.407 million, compared to a net loss of $15.060 million in the same period of 2024[10] - Net income attributable to common stockholders for the nine months ended September 30, 2025, was $263,743 thousand, compared to $7,304 thousand in 2024, representing a significant increase[12] - Basic net income per common share rose to $14.73 for the nine months ended September 30, 2025, compared to $0.40 in the prior year[12] - Net income for the nine months ended September 30, 2025, was $295,395 thousand, a significant increase from $11,856 thousand in the same period of 2024[44] Production and Sales - Natural gas production volumes for the three months ended September 30, 2025, were 90.873 million Mcf, compared to 88.920 million Mcf in the same period of 2024, reflecting a 2.2% increase[7] - Total sales from oil and condensate for the three months ended September 30, 2025, were $37.406 million, up from $29.467 million in the same period of 2024, a 27% increase[10] - Natural gas production volumes for the nine months ended September 30, 2025, were 247.390 million Mcf, down from 266.011 million Mcf in the same period of 2024, a decrease of 7%[8] - Average price of natural gas, including settled derivatives, rose to $2.95 per Mcf for the three months ended September 30, 2025, compared to $2.75 per Mcf in the same period of 2024, a 7.3% increase[7] - Average price of oil and condensate, including settled derivatives, decreased to $63.31 per Bbl for the nine months ended September 30, 2025, from $71.72 per Bbl in the same period of 2024, a decline of 11.7%[8] Operating Expenses and Cash Flow - Total operating expenses decreased to $602,624 thousand for the nine months ended September 30, 2025, from $640,024 thousand in 2024, a reduction of approximately 5.8%[12] - The company reported a net cash provided by operating activities of $617,761 thousand for the nine months ended September 30, 2025, compared to $501,185 thousand in 2024, an increase of 23.2%[20] - Adjusted free cash flow for the nine months ended September 30, 2025, was $204,628 thousand, compared to $131,601 thousand in 2024, representing a growth of approximately 55%[51] - For the three months ended September 30, 2025, adjusted free cash flow was $103,436 thousand, compared to $72,557 thousand in 2024, marking an increase of approximately 42%[46] Capital Expenditures and Debt - Capital expenditures for 2025 are estimated at approximately $390 million for base operations, with an additional $30 million for discretionary appraisal and $35 million for discretionary development[22] - Capital expenditures incurred for the nine months ended September 30, 2025, totaled $379,615 thousand, an increase from $332,633 thousand in the same period of 2024[51] - The company’s long-term debt as of September 30, 2025, was $691,666 thousand, slightly down from $702,857 thousand as of December 31, 2024[16] - Interest expense for the nine months ended September 30, 2025, was $40,677 thousand, down from $46,027 thousand in 2024, reflecting a decrease of about 12%[51] Adjusted Metrics - Adjusted net income for the three months ended September 30, 2025, is reported at $90.25 million, compared to $61.85 million for the same period in 2024[36] - Adjusted EBITDA for the three months ended September 30, 2025, is $213.10 million, an increase from $178.09 million in the prior year[41] - Adjusted EBITDA for the nine months ended September 30, 2025, reached $643,682 thousand, compared to $528,252 thousand for the same period in 2024, reflecting a growth of approximately 22%[44] Operational Efficiency - The company reported a total change in operating assets and liabilities of $(14,555) thousand for the nine months ended September 30, 2025, compared to $(21,247) thousand in 2024, indicating improved operational efficiency[51] - Non-recurring general and administrative expenses for the nine months ended September 30, 2025, were $1,438 thousand, slightly lower than $1,561 thousand in 2024[51] Future Guidance and Plans - The company plans to maintain its 2025 guidance based on commodity strip prices as of October 14, 2025, without any property acquisitions or divestitures[21] - Average daily gas equivalent production is projected to be approximately 1,040 MMcfe/day for the year ending December 31, 2025[22] - Average daily liquids production is expected to range from 18.0 MBbl/day to 20.5 MBbl/day, with gas comprising about 89% of total production[22] - The company anticipates lease operating expenses to be between $0.19 and $0.22 per Mcfe for 2025[22] - The company anticipates total discretionary acreage acquisitions between $75 million and $100 million, with targeted acquisitions of $15.7 million for the nine months ended September 30, 2025[52] Derivative Gains and Losses - Non-cash derivative gains/losses for the three months ended September 30, 2025, include a gain of $33.05 million, contrasting with a loss of $46.91 million in the same period of 2024[41] - The company has fixed price swaps for natural gas totaling 270 BBtupd at a weighted average price of $3.82 per MMBtu for 2025[25] - The company’s oil fixed price swaps volume is 3,000 Bblpd at a weighted average price of $73.29 per Bbl[25]

Financial Performance - Net sales for Q3 2025 were $161.9 million, an increase of 7.6% from $150.5 million in Q3 2024, driven by higher sales volume and tariff-related price increases[8] - Gross profit for Q3 2025 increased by 17.7% to $57.3 million, with gross margin expanding by 300 basis points to 35.4%[10] - Net income for Q3 2025 was $8.1 million, up 37.7% from $5.9 million in Q3 2024, resulting in an earnings per diluted share of $0.07 compared to $0.05 in the prior year[12] - Adjusted EBITDA for Q3 2025 rose by 28.5% to $38.3 million, with an adjusted EBITDA margin of 23.7%, an increase of 390 basis points from the previous year[12] - For the first nine months of 2025, net sales reached $446.0 million, a 5.9% increase from $421.2 million in the prior-year period[13] - Net income for the three fiscal quarters ended September 27, 2025, was $18,135,000, a 60.5% increase from $11,310,000 for the same period in 2024[46] - Adjusted EBITDA for the three fiscal quarters ended September 27, 2025, was $89,354,000, representing a 16.6% increase from $76,598,000 in the prior year[48] - Net sales for the three fiscal quarters ended September 27, 2025, reached $445,962,000, up 5.9% from $421,247,000 in the same period of 2024[48] Guidance and Projections - The company narrowed its net sales guidance for 2025 to a range of $540-$550 million, reflecting a projected 7% growth[20] - Adjusted EBITDA guidance for 2025 is set at $92-$98 million, indicating a 19% growth at the midpoints[20] - Capital expenditures for 2025 are revised to a range of $22-$24 million, down from the previous estimate of $27-$33 million[24] - The company expects fiberglass pools to gain another percentage point of market share, reaching approximately 24% of total U.S. in-ground pool sales in 2025[22] Debt and Liquidity - Latham's net debt leverage ratio improved to 2.3 from 3.0 in the previous quarter, with total debt at $281.1 million[17] - The company reported a net debt of $277,823,000 as of September 27, 2025, with a net debt leverage ratio calculated based on last twelve months of Adjusted EBITDA[41] - Total current assets increased to $240,915,000 from $178,298,000 as of December 31, 2024, reflecting improved liquidity[44] - Total liabilities rose to $436,065,000 from $406,985,000 as of December 31, 2024, indicating a slight increase in leverage[44] - The company’s cash balance increased to $70,518,000 from $56,398,000, enhancing its financial flexibility[44] Operating Expenses - Selling, general, and administrative expenses for the quarter were $28,586,000, slightly up from $28,336,000 in the previous year[42] - The company incurred $4,934,000 in acquisition costs, significantly lower than $64,046,000 in the previous year[46] - Stock-based compensation expense for the three fiscal quarters ended September 27, 2025, was $5,332,000, slightly up from $5,187,000 in the prior year[48] Other Financial Metrics - The net cash provided by operating activities for the three fiscal quarters ended September 27, 2025, was $40,121,000, compared to $55,150,000 in the prior year, reflecting a decrease of 27.3%[46] - The adjusted EBITDA margin improved to 20.0% for the three fiscal quarters ended September 27, 2025, compared to 18.2% in the same period of 2024[48] - Cash at the end of the period was $70,518,000, an increase from $59,862,000 at the end of the same period in 2024[46] - The company experienced a foreign currency loss of $2,878,000 for the three fiscal quarters ended September 27, 2025, compared to a gain of $1,668,000 in the same period of 2024[48] Market Conditions - The company anticipates future operating results to be influenced by macroeconomic conditions and changes in consumer demand[37]

Toast Announces Third Quarter 2025 Financial Results Annualized recurring run-rate (ARR) grew 30%, crossing $2.0 billion as of September 30, 2025 Added approximately 7,500 net new Locations in third quarter 2025 Net income was $105 million and Adjusted EBITDA was $176 million in third quarter BOSTON, MA – November 4, 2025 – Toast (NYSE: TOST), the all-in-one digital technology platform built for restaurants, today reported financial results for the third quarter ended September 30, 2025. "Toast delivered an ...